Comparative Pharmacology
Head-to-head clinical analysis: CIPRODEX versus SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRODEX versus SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH.
CIPRODEX vs SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication; dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis. Together, they provide sequential blockade of folate metabolism, leading to bactericidal activity.
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension: 4 drops into affected ear(s) twice daily for 7 days.
1 double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) orally every 12 hours for most infections; single-strength tablet (400 mg/80 mg) is used for prophylaxis: 1 tablet orally daily.
None Documented
None Documented
Ciprofloxacin: terminal elimination half-life 3-5 hours (prolonged to 5-10 hours in renal impairment). Dexamethasone: biological half-life 36-54 hours.
Sulfamethoxazole: 10-12 hours (prolonged in renal impairment); Trimethoprim: 8-11 hours (prolonged in hepatic impairment).
Ciprofloxacin: 50-70% renal (glomerular filtration and tubular secretion), 20-35% biliary/fecal. Dexamethasone: renal elimination of metabolites, <5% unchanged.
Sulfamethoxazole: primarily renal (70-90% as unchanged drug and acetylated metabolite); Trimethoprim: renal (50-60% unchanged, rest as metabolites); small biliary/fecal elimination (<5% each).
Category C
Category D/X
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic